Genitourinary Clinical Trials

With an emphasis on transdisciplinary translational research, the OSUCCC-James facilitates investigator-initiated early phase clinical trials and participates in many cooperative groups.

Protocol No.PITitle
OSU-09085Ronney AbazaRetrospective & Prospective Analysis of Robotic Surgery for Renal Tumors
OSU-10071Ronney AbazaRetrospective/Prospective Analysis of surgical outcomes of robotic cystectomy at Ohio State University/The James
OSU-11106Ronney AbazaRetrospective Cost Comparison Analysis of Laparoscopic and Robotic Assisted Laparoscopic Nephrectomy at The Ohio State Medical Center and The James Cancer Hospital
OSU-12140Arnab ChakravartiMolecular markers of prostate carcinoma
CALGB-150403Steven ClintonEmbedded companion to CALGB 90202: N-telopeptide as a prognostic marker for PCa patients on 90202
OSU-10037Brian FochtHabitual Physical activity Patterns, Muscle Mass, and Physical Function in Men Undergoing Androgen Deprivation Therapy (ADT)
OSU-12008Brian FochtThe Intensive Diet and Exercise Adherence Trial-Pilot (IDEA-P): A Feasibility Study of a Lifestyle Intervention in Men Undergoing Androgen Deprivation Therapy
OSU-08063Michael KnoppImaging of the Bladder Tumor Using Clinical 3 Tesla MRI and Ex-Vivo Ultra-high-field MRI
OSU-07042Michael KnoppImaging of the Prostate Gland Using High Field Strength 3T MRI
OSU-12158Tim LautenschlaegerBiomarker Identification for Bladder Cancer Patients
OSU-12042Greg LesinskiThe Effect of a Soy Bread Diet Intervention on Immune Function in Men with Prostate Cancer
RTOG-0534Douglas MartinA Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy
OSU-0390J. Paul MonkA Banking Facility for Biological Samples From Patients with Renal Cell Carcinoma
CALGB-90203J. Paul MonkA Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer
CALGB-150413J. Paul MonkEmbedded companion to CALGB 90203:
CALGB-150412J. Paul MonkEmbedded companion to CALGB 90203:
SWOG-S1216J. Paul MonkA Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
OSU-13256J. Paul MonkA randomized open-label phase IIa study evaluating the efficacy and safety of radium-223 dichloride in combination with abiraterone acetate or enzalutamide in subjects with castration-resistant prostate cancer (CRPC) who have bone metastases
OSU-11151J. Paul MonkPhase I/II Study of High Dose Interleukin 2, Aldesleukin, in Combination with the Histone Deacetylase Inhibitor Entinostat in Patients with Metastatic Renal Cell Carcinoma
OSU-14108Amir MortazaviA phase I, open-label, multi-center, dose escalation study of oral BGJ398, a pan FGF-R kinase inhibitor, in adult patients with advanced solid malignancies
OSU-07110Amir MortazaviOptimizing Human Urine Protein Extraction
CALGB-150609Amir MortazaviEmbedded Companion to CALGB-90601
CALGB-60707Amir MortazaviEmbedded Companion to CALGB-90601
OSU-13120Thomas OlenckiA Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy
SWOG-S1011Kamal PoharA Phase III Surgical Trial to Evaluate the Benefit of a Standard versus an Extended Pelvic Lymphadenectomy Performed at time of Radical Cystectomy for Muscle Invasive Urothelial Cancer
OSU-11084Ahmad ShabsighOpen Vs Robotic-Assisted Radical Cystectomy: A Randomized Trial
RTOG-0926Evan WuthrickA Phase II Protocol For Patients With Stage T1 Bladder Cancer To Evaluate Selective Bladder Preserving Treatment By Radiation Therapy Concurrent With Radiosensitizing Chemotherapy Following A Thorough Transurethral Surgical Re-Staging

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 460 W. 10th Avenue, Columbus, OH 43210 Phone: 1-800-293-5066 | Email: